Ocular toxicity of AUY922 in pigmented and albino rats
Creators
- 1. Preclinical Safety, Novartis Pharma AG, Basel (Switzerland)
- 2. University of Wisconsin School of Medicine and Public Health, Madison, WI (United States)
- 3. Ocular Services on Demand, Madison, WI (United States)
- 4. Preclinical Safety, Novartis Pharmaceuticals Corporation, East Hanover, NJ (United States)
- 5. Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH (United States)
- 6. Covance Laboratories Inc., Madison, WI (United States)
- 7. Comparative Ophthalmic Research Laboratory (CORL), University of Wisconsin, Veterinary Medical Teaching Hospital, Madison, WI (United States)
- 8. Drug Metabolism and Pharmacokinetics, Novartis Pharmaceuticals Corporation, East Hanover, NJ (United States)
- 9. Biologics Clinical Pharmacology, Janssen BioTherapeutics at Johnson & Johnson, Spring House, PA (United States)
- 10. Oncology Global Development, Novartis Pharma AG, Basel (Switzerland)
Description
AUY922, a heat shock protein 90 inhibitor is associated with ocular adverse events (AEs). To provide a better understanding of ocular AEs in patients, 4 investigative studies were performed in a step-wise approach to assess retinal structure and function in pigmented (Brown Norway) and albino (Wistar) rats. In rats administered 30 mg/kg of AUY922, the AUC0–24 h and Cmax are comparable to that in patients at 70 mg/m2. AUY922 at ≥ 30 mg/kg was poorly tolerated by rats with morbidity or mortality generally after the third weekly treatment. Electroretinography (ERG) changes were observed at doses ≥ 30 mg/kg. The ERG changes were dose dependent, consistent with an effect on the photoreceptors, and fully reversible. The ERG effects could not be minimized by decreasing the Cmax while maintaining AUC. Histopathological changes were seen mainly when rats were administered AUY922 at 100 mg/kg. The 2-hour infusion of AUY922 at 100 mg/kg caused disorganization of the outer segment photoreceptor morphology in male Brown Norway rats; the severity of the disorganization increased with the number of administrations, but was reversible during a 4-week posttreatment period. There was no major difference in ocular response between Brown Norway and Wistar rats. No changes in serum iron levels, and no changes in rhodopsin, PDE6α, β-transducin concentrations, or retinal pigment epithelium-specific protein RPE65 expression were observed after single and multiple infusions of AUY922 at 100 mg/kg compared to vehicle-treated controls. AUY922 retinal toxicity in rats recapitulates and further characterizes that reported in patients and is shown to be reversible, while a precise molecular mechanism for the effect was not determined. - Highlights: • Ocular toxicity of AUY922 was assessed in Brown Norway and Wistar rats. • AUY922 at ≥ 30 mg/kg was generally not well tolerated by rats. • Electroretinography (ERG) changes were observed at doses ≥ 30 mg/kg. • ERG changes at doses ≥ 30 mg/kg were dose-dependent, and fully reversible.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.taap.2016.08.025Additional details
Identifiers
- DOI
- 10.1016/j.taap.2016.08.025;
- PII
- S0041-008X(16)30248-4;
Publishing Information
- Journal Title
- Toxicology and Applied Pharmacology
- Journal Volume
- 309
- Journal Page Range
- p. 55-62
- ISSN
- 0041-008X
- CODEN
- TXAPA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49040300
- Subject category
- S60: APPLIED LIFE SCIENCES; S54: ENVIRONMENTAL SCIENCES;
- Descriptors DEI
- AUGER ELECTRON SPECTROSCOPY; CONCENTRATION RATIO; DISEASE INCIDENCE; DOSES; EPITHELIUM; HEAT-SHOCK PROTEINS; INFUSION; IRON; MORPHOLOGY; MORTALITY; PATIENTS; RATS; RHODOPSIN; TOXICITY
- Descriptors DEC
- ANIMAL TISSUES; ANIMALS; BODY; DIMENSIONLESS NUMBERS; ELECTRON SPECTROSCOPY; ELEMENTS; INTAKE; MAMMALS; METALS; ORGANIC COMPOUNDS; PIGMENTS; PROTEINS; RODENTS; SPECTROSCOPY; TRANSITION ELEMENTS; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.